PubMed · 2001 · 168 citations · 73 references
MedicineCancer BiologyOncologyEarly DetectionGastrointestinal OncologyMolecular OncologyBiomarker DiscoveryCancer BiomarkersCancer DetectionCancer Early DetectionColorectal CancerEarly Cancer DetectionColorectal Cancer BiomarkersColorectal Cancer PathologyColorectal Cancer PrognosisColorectal Carcinogenesis PathophysiologyEarly Cancer Detection MarkersGastrointestinal Disease BiomarkersPreinvasive NeoplasiaSurrogate Endpoints
There is an increasing demand for biomarkers in colon cancer for risk assessment, early detection, prognosis, and surrogate end points. A number of biomarkers have been identified for early detection of colon cancer, although the risk factors have not been identified extensively. The major advances in understanding colorectal cancer include the identification and the involvement of APC, p53, and Ki-ras in the development and progression of the disease, the identification of the aberrant crypt foci as an early preinvasive lesion, and its relation to the development of cancer. Detecting malignant neoplasms in the early stages offers clinical advantages; therefore, the National Cancer Institute has established an Early Detection Research NETWORK: The emphasis of the network is on translational research and collaboration among scientists.
73
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
Cancer: Principles and Practice of Oncology.
Annals of Internal Medicine · 1991 · 8.5K citations
Medicine, Oncology, Oncology Nursing +10
C. Richard Boland, Stephen N. Thibodeau, Stanley R. Hamilton et al. · PubMed · 1998 · 4.1K citations
Life Sciences, Genetics, Oncology +17
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Patrice J. Morin, Andrew B. Sparks, Vladimír Kořínek et al. · Science · 1997 · 3.9K citations
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
David Malkin, Frederick P. Li, Louise C. Strong et al. · Science · 1990 · 3.8K citations
Life Sciences, Genetics, Oncology +17